Tickerover
Healthcare

CORT Stock Analysis

Corcept Therapeutics Incorporated · current price $113.89 (-2.64% today)

Top-tier setup — 32% revenue growth. Momentum, fundamentals and macro indicators are aligned.
★★★★★
Top Tier
📊

The six-pillar scorecard

Momentum
71
Trending up strong
price trend
Growth
26
Barely growing
sales & profit growth
Quality
94
High quality
profitability & balance sheet
Valuation
75
Looks cheap
is the price fair?
Sentiment
42
Mixed views
analyst & crowd mood
Risk
62
Moderate risk
volatility & drawdown

Each pillar is scored 0-100 inside the stock’s own peer group, so a chipmaker is measured against chipmakers. These are quality descriptors, not buy or sell signals.

📉

The picture

What drove the scoreThe seven components contributing most, each read out of 100.
GrowthGrowth: 7878RSI zoneRSI zone: 100100Trend strengthTrend strength: 100100Relative strengthRelative strength: 8585Earnings qualityEarnings quality: 8282Earnings accelerationEarnings acceleration: 100100News sentimentNews sentiment: 9595
Margin profileWhat survives each step down the income statement.
GrossGross: 98.3%98.3%OperatingOperating: 16.1%16.1%NetNet: 6.6%6.6%Free cash flowFree cash flow: 12.9%12.9%
EPS surpriseReported EPS against estimate, last four quarters.
2026-06: +535.3% vs estimate+535%2026-062026-03: -111.3% vs estimate-111%2026-032025-12: -39.4% vs estimate-39%2025-122025-09: +18.5% vs estimate+19%2025-09
👁

Hype Check

Reading CORT’s price and volume history…

The audit — what has to hold for this thesis

Checking the areas that decide this thesis…

AI-generated from the company’s own filings and recent coverage, and it can be incomplete or wrong. A PASS is a reading of the cited evidence, not a verified fact and not a reason to buy. Follow each citation to the source.

🛡

Dilution Check

Reading CORT’s filings…

📣

Latest earnings

LAST EARNINGS Corcept Therapeutics Incorporated (CORT)

Latest earnings

EPS
$0.16 vs $0.14 est · +18.5% vs estimate BEAT
Revenue
$256.1M · +23.4% YoY
Stock reaction (1M)
-3.8%
Beat streak
2 of last 4 quarters
💰

Valuation

P/E
247.6×
Forward P/E
25.9×
PEG
0.81
Price / Sales
14.8×
Price / Book
17.4×
EV / EBITDA
1485.8×
Analyst target
$141.00
Target range
$50.00 – $165.00
Implied upside
+23.8%
🩺

Financial health

Gross margin
98.3%
Operating margin
16.1%
Net margin
6.6%
FCF margin
12.9%
Return on equity
8.2%
Debt / equity
0.01
Revenue growth YoY
+31.7%
EPS growth YoY
+24.1%
📈

Technicals

$28.6652-week range$126.38
RSI (14)
54
50-day MA
$100.96
200-day MA
$65.92
ATR (14)
3.95
Beta
0.46
1-month return
-3.8%
🗓️

Earnings

QuarterEPSEst.SurpriseResult
2025-09-30$0.16$0.14+18.5%Beat
2025-12-31$0.20$0.33-39.4%Miss
2026-03-31$-0.30$-0.14-111.3%Miss
2026-06-30$0.36$0.06+535.3%Beat
Beat 2 of the last 4 quarters.
🏛️

Ownership & risk

Short % of float
0.12%
Beta
0.46
📰

Latest news on CORT

🔗

Similar stocks in Healthcare

Frequently asked

What is CORT's Quant Score?

Corcept Therapeutics Incorporated (CORT) currently has a TickerMover Quant Score of 75/100, rated ★★★★★ Top Tier. The Quant Score is a quantitative composite across six research pillars — momentum, quality, growth, valuation, sentiment and risk. It is research information, not investment advice.

Is Corcept Therapeutics Incorporated (CORT) a buy?

TickerMover does not give buy or sell recommendations. CORT scores 75/100 (★★★★★ Top Tier) on our quantitative research model — a screening signal, not a personal recommendation. Do your own research, and consider an FCA-authorised adviser before investing.

How often is CORT's score updated?

CORT's Quant Score and underlying data refresh through US market hours (about every five minutes), using public market and fundamental data.

Get the full live dashboard

Real-time scoring, conflict detection, Reverse DCF and peer comparison — free while in beta.

Open the dashboard for CORT →